Follicle-stimulating hormone

Pharmaceutical Biotechnology: Fundamentals and Applications, Third Edition

Volumn , Issue , 2016, Pages 399-403

  Sam, Tom ^a  

^a NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84903799677     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (14)

1. Daya S. (2002). Updated meta-analysis of recombinant follicle stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertility Sterility 77:711-714.
2. De Boer W, Mannaerts B. (1990). Recombinant follicle stimulating hormone. II. Biochemical and biological characteristics. In: Crommelin DJA, Schellekens H, eds. From Clone to Clinic, Developments in Biotherapy, Vol. 1. Dordrecht: Kluwer Academic Publishers, 253-259.
3. De Leeuw R, Mulders J, Voortman G, Rombout F, Damm J, Kloosterboer L. (1996). Structure-function relationship of recombinant follicle stimulating hormone (Puregon®). Mol Human Reprod 2:361-369.
4. Dias JA. (2001). Is there any physiological role for gonadotrophin oligosaccharide heterogeneity in humans? II. A biochemical point of view. Human Reprod 16:825-830.
5. European Public Assessment Report Gonal-F (Follitropin alpha), CPMP/415/95, revision 8, 3 November 2004. European Agency for the Evaluation of Medicinal Products.
6. EuropeanPublicAssessmentReport Puregon (Follitropinbeta), CPMP/003/96, revision 9, 19 May 2005. European Agency for the Evaluation of Medicinal Products.
7. Geurts TBP, Peters MJH, Bruggen JGC, van de Boer W, Out HJ. (1996). Puregon® (Org 32489)-Recombinant human follicle-stimulating hormone. Drugs Today 32:239-58.
8. Howles CM. (1996). Genetic engineering of human FSH (Gonal-F®) Human Reprod Update 2:172-191.
9. Olijve W, de Boer W, Mulders JWM, van Wezenbeek PMGF. (1996). Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon®). Mol Human Reprod 2:371-382.
10. Out HJ, Mannaerts BMJL, Driessen SGAJ, Coelingh Bennink HJT. (1996). Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: More oocytes, more pregnancies. Results from five comparative studies. Human Reprod Update 2:162-171.
11. Sansom C, Markman O. (2007). Glycobiology. Scion Publishing Ltd, p. 374.
12. Van Wezenbeek P, Draaijer J, Van Meel F, et al. (1990). Recombinant follicle stimulating hormone. I. Construction, selection and characterization of a cell line. In Crommelin DJA and Schellekens H. (eds), From Clone to Clinic, Developments in Biotherapy. Kluwer, Amsterdam, pp. 245-251.
13. Voortman G, van de Post J, Schoemaker RC, van Gerwen J. (1999). Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon®) by Pen-injector and syringe. Human Reprod 14:1698-1702.
14. Woodcock J. Griffin J. Behrman R, et al. (2007). The FDA's assessment of follow-on protein products: a historical perspective. Nature Reviews Drug Discovery 6:437-422.